You're contacting media contact of this press release

Title: Cellomatics Biosciences Limited Nominated for the Go Global Awards 2025

United States, 8th Oct 2025 - Cellomatics Biosciences Limited, a specialist preclinical contract research organisation (CRO) dedicated to supporting global drug discovery and development, has been nominated for the prestigious Go Global Awards 2025, scheduled for November 18–19, 2025, at One Great George Street, Westminster, London. This nomination recognises the company’s excellence in delivering innovative, high-quality, and data-driven solutions that accelerate pharmaceutical research worldwide.Founded in 2015 and headquartered in Nottingham, United Kingdom, Cellomatics Biosciences provides bespoke cell-based assay services that enable biotech and pharmaceutical companies to de-risk decision-making and speed up R&D programmes. The company’s expertise spans immuno-inflammation, respiratory, oncology, and ophthalmology, leveraging advanced human in vitro models to generate actionable insights that drive scientific and clinical progress.With a talented team of scientists and professionals, Cellomatics has established itself as a trusted partner through its client-centric, collaborative approach. By combining deep expertise in cell biology with cutting-edge research techniques, the company empowers its partners to translate groundbreaking science into real-world therapies more efficiently.Shailendra Singh, CEO and Founder of Cellomatics Biosciences Limited, will represent the company at the Go Global Awards. Under his leadership, Cellomatics continues to advance preclinical research and strengthen its role in driving innovation across the global life sciences sector.This nomination underscores Cellomatics’ commitment to accelerating therapeutic innovation, improving global healthcare, and supporting transformative drug development.For more information, visit: ht...

This press release is issued by King Newswire